EHA 2021 | Next steps for genetic testing in CLL
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of the role of genetic testing in the treatment of patients with chronic lymphocytic leukemia (CLL), highlighting the role of IgHV status and TP53 mutations in excluding certain therapies. Dr Mato also talks on the need to use biomarkers to direct therapy and the need for universal testing and reporting of biomarkers. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Anthony Mato, MD, MSCE, has received research support from TG Therapeutics, Pharmacyclics, AbbVie, LOXO, Johnson & Johnson, Acerta/AZ, Regeneron, DTRM BioPharma, Sunesis, Loxo Oncology, Adaptive, Nurix, Genmab; and has participated in an advisory, consultancy or DSMB role for TG Therapeutics, Pharamacyclics, Adaptive, AbbVie, Johnson & Johnson, Acerta/AZ, DTRM BioPharma, Sunesis, Celgene, Versatem, Nurix, Genmab and LOXO.
